ethyl 2-methyl-2-(pyridin-2-yl)propanoate | 20092-97-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: ethyl 2-methyl-2-(pyridin-2-yl)propanoate
• 英文别名: ethyl 2-methyl-2-pyridin-2-ylpropanoate
• CAS: 20092-97-1
• 化学式: C₁₁H₁₅NO₂
• mdl: MFCD18855433
• 分子量: 193.246
• InChiKey: BMMYGYKRBVTVHD-UHFFFAOYSA-N

物化性质

• 沸点：
  70-78 °C(Press: 0.6 Torr)
• 密度：
  1.039±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 2-methyl-2-(pyridin-2-yl)propanoate 在 sodium hydroxide 作用下， 以 水 为溶剂， 生成 Sodium 2-methyl-2-(pyridin-2-yl)propanoate
  参考文献：
  名称：

  Non-acidic pyrazole EP1 receptor antagonists with in vivo analgesic efficacy

  摘要：

  Replacement of the carboxylic acid group in a series of previously described methylene-linked pyrazole EP1 receptor antagonists led to the discovery of amide, reversed amide and carbamate derivatives. Two compounds, 10a and 10b, were identified as brain penetrant compounds and both demonstrated efficacy in the CFA model of inflammatory pain. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.04.018
• 作为产物：
  描述：

  异丁酸乙酯 在 乙醚 、 三苯甲基钠 作用下， 生成 ethyl 2-methyl-2-(pyridin-2-yl)propanoate
  参考文献：
  名称：

  Mechanism of the Decarboxylation of α-Pyridylacetic Acid¹

  摘要：

  DOI：

  10.1021/ja01157a040

文献信息

• 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS
  申请人：Forma Therapeutics, Inc.

  公开号：US20160222028A1

  公开（公告）日：2016-08-04

  The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X 1 , X 2 , X 3 , X 4 , Y 1 , Y 2 , Y 3 , and Y 4 are described herein.

  本公开涉及抑制锌依赖性组蛋白去乙酰化酶（HDACs）的抑制剂，用于治疗与HDAC（例如HDAC6）相关的疾病或疾病，其具有以下式I： 其中R、L、X1、X2、X3、X4、Y1、Y2、Y3和Y4如本文所述。
• Rhodium(III)-Catalyzed Oxidative Cross-Coupling of Unreactive C(sp³)–H Bonds with C(sp²)–H Bonds
  作者：Guangying Tan、Jingsong You

  DOI：10.1021/acs.orglett.7b02167

  日期：2017.9.15

  The development of the oxidative cross-coupling of unreactive C(sp3)–H bonds with (hetero)arene C(sp2)–H bonds is considerably appealing, yet conceptually and practically challenging. Here, we disclose the rhodium-catalyzed oxidative heteroarylation of unactivated C(sp3)–H bonds with heteroarene C(sp2)–H bonds. This method provides a step-economic route to β-heteroarylated 2-ethylpyridine derivatives

  未反应的C（sp 3）-H键与（杂）芳烃C（sp 2）-H键的氧化交叉偶联的发展颇具吸引力，但在概念和实践上都具有挑战性。在这里，我们公开了未活化的C（sp 3）-H键与杂芳烃C（sp 2）-H键的铑催化氧化杂芳基化反应。该方法为β-杂芳基化的2-乙基吡啶衍生物的制备提供了分步骤的经济途径，该衍生物具有相对较宽的底物范围，对敏感官能团的高耐受性和高选择性。该方案还可以扩展到8-甲基喹啉衍生物和杂芳烃之间的偶联反应。
• [EN] AMINOPYRAZOLE DERIVATIVES AS GSK-3 INHIBITORS<br/>[FR] DERIVES D'AMINOPYRAZOLE EN TANT QU'INHIBITEURS DE LA GSK-3
  申请人：PFIZER PROD INC

  公开号：WO2005051919A1

  公开（公告）日：2005-06-09

  The present invention provides compounds of formula (I) the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers, and prodrugs, wherein R1, R2, and R3 are as defined herein; pharmaceutical compositions thereof; combinations thereof; and uses thereof in the treatment of, inter alia, conditions, diseases, and symptoms including, inter alia, Alzheimer's Disease, cancer, dementia, depression, diabetes, hair loss, schizophrenia, and stroke.

  本发明提供了式（I）化合物及其立体异构体和前体药物，以及该化合物、立体异构体和前体药物的药用可接受盐，其中R1、R2和R3如本文所定义；其药用组合物；其组合物；以及在治疗包括阿尔茨海默病、癌症、痴呆、抑郁症、糖尿病、脱发、精神分裂症和中风等疾病、疾病和症状中的用途。
• Aminopyrazole Derivatives as Gsk-3 Inhibitors
  申请人：Benbow W. John

  公开号：US20070276010A1

  公开（公告）日：2007-11-29

  The present invention provides compounds of formula (I) the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers, and prodrugs, wherein R 1 , R 2 , and R 3 are as defined herein; pharmaceutical compositions thereof; combinations thereof; and uses thereof in the treatment of, inter alia, conditions, diseases, and symptoms including, inter alia, Alzheimer's Disease, cancer, dementia, depression, diabetes, hair loss, schizophrenia, and stroke.

  本发明提供了式(I)的化合物及其立体异构体和前药，以及所述化合物、立体异构体和前药的药学上可接受的盐，其中R1、R2和R3如本文所定义；其制备的药物组合物；以及其在治疗阿尔茨海默病、癌症、痴呆、抑郁症、糖尿病、脱发、精神分裂症和中风等病症和症状中的使用。
• Aminopyrazole derivatives as GSK-3 inhibitors
  申请人：Pfizer Inc.

  公开号：US07671072B2

  公开（公告）日：2010-03-02

  The present invention provides compounds of formula (I) the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers, and prodrugs, wherein R1, R2, and R3 are as defined herein; pharmaceutical compositions thereof; combinations thereof; and uses thereof in the treatment of, inter alia, conditions, diseases, and symptoms including, inter alia, Alzheimer's Disease, cancer, dementia, depression, diabetes, hair loss, schizophrenia, and stroke.

  本发明提供了式（I）的化合物及其立体异构体和前药，以及该化合物、立体异构体和前药的药学上可接受的盐，其中R1、R2和R3如本文所定义；其制药组合物；以及其在治疗阿尔茨海默病、癌症、痴呆、抑郁症、糖尿病、脱发、精神分裂症和中风等疾病、症状中的应用。

表征谱图